Sanofi has infused an additional $625 million into its corporate venture capital arm, Sanofi Ventures, bringing total funds to $1.4 billion. This strategic move aims to strengthen investments in emerging biotech companies amid a challenging funding climate, enabling Sanofi to lead or co-lead financing rounds and gain early access to cutting-edge technologies. The investment underscores the growing role of corporate venture capital in biotech innovation and partnerships, supporting companies across all development stages from seed to crossover financing.